会员体验
专利管家(专利管理)
工作空间(专利管理)
风险监控(情报监控)
数据分析(专利分析)
侵权分析(诉讼无效)
联系我们
交流群
官方交流:
QQ群: 891211   
微信请扫码    >>>
现在联系顾问~
热词
    • 2. 发明申请
    • CRYSTALLINE PEMETREXED DIPOTASSIUM PROCESS
    • 水晶硅酸盐工艺
    • WO2014060959A1
    • 2014-04-24
    • PCT/IB2013/059384
    • 2013-10-16
    • SHILPA MEDICARE LIMITED
    • SHRAWAT, Vimal Kumar., RafiuddinSINGH, Vinod KumarPIPAL, Bhagat RajCHATURVEDI, Akshay Kant
    • C07D487/04A61K31/519A61P35/00
    • A61K31/519C07D487/04
    • The present invention provides crystalline pemetrexed dipotassium hemiheptahydrate (I) - characterized by X-ray powder diffraction pattern comprising at least 5 characteristic 29° peaks selected from the XRPD peak set of 5.00, 13.70, 14.90, 15.20, 16.90, 20.00, 20.50, 21.40, 23.6, 24.2, 25.10, 27.5 and 28.30 ± 0.20 29°, DSC isotherm comprising the endothermic peaks ranging between 65 to 85°C (Peak -1), 86 to 105°C (Peak -2), 120 to 132°C (Peak -3), 250 to 265°C (Peak -4), and IR absorption characteristic peaks at approximately 2936 cm -1 , 2857 cm -1 , 1396 cm -1 , 1184 cm -1 , 1158 cm -1 , 1092 cm -1 , 1076 cm -1 , 819 cm -1 and 788 cm -1 useful as active pharmaceutical ingredient in pharmaceutical compositions for the treatment of cancer. The invention also provides process for preparing pemetrexed dipotassium hemiheptahydrate (I) and its pharmaceutical composition thereof.
    • 本发明提供结晶培美曲塞半水合二钙(I) - 特征在于X射线粉末衍射图,其包含至少5个特征29°峰,其选自XRPD峰组5.00,133.90,14.90,15.20,16.90,20.20.20.40.40 ,23.6,24.2,25.10,27.5和28.30±0.20 29°,DSC等温线包括65至85℃(峰-1),86至105℃(峰-2),120至132℃之间的吸热峰 (峰-3),250至265℃(峰-4),IR吸收特征峰在约2936cm -1,2857cm -1,1396cm -1,1184cm -1,1158cm -1,1092 cm-1,1076cm-1,819cm-1和788cm-1用作用于治疗癌症的药物组合物中的活性药物成分。 本发明还提供了制备培美曲塞半水合二钾(I)及其药物组合物的方法。